ziprasidone has been researched along with quetiapine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P | 1 |
| Arnt, J; Skarsfeldt, T | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Bristow, LJ; Hutson, PH; Rowley, M | 1 |
| Chen, XL; Kang, J; Kongsamut, S; Rampe, D; Roehr, J | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Wermuth, CG | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Freeman, BB; Rankovic, Z; Yang, L | 1 |
5 review(s) available for ziprasidone and quetiapine
| Article | Year |
|---|---|
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.
Topics: Animals; Antipsychotic Agents; Humans | 1998 |
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists | 2001 |
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship | 2019 |
11 other study(ies) available for ziprasidone and quetiapine
| Article | Year |
|---|---|
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1996 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Cation Transport Proteins; Cell Line; Clinical Trials as Topic; Cricetinae; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Radioligand Assay; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Trans-Activators; Transcriptional Regulator ERG | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |